Eli Lilly Archives

News and Trends 3 Mar 2023

Lilly to develop Confo pain drug

Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases. The agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design (SBDD) platform and Lilly’s drug development and commercialization […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Study of injection to treat schizophrenia to begin after $3M payment received

A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […]

September 1, 2022 - 2 minutesmins - By Liza Laws

News and Trends 19 Aug 2022

Beyond Biotech podcast 10: Endpoint Health, Nevrargenics, Triastek

This week our guests on the podcast are Xianghao Zuo, deputy director of R&D at Triastek; Endpoint Health CEO Jason Springs; and Andy Whiting, CEO of Nevrargenics. Triastek and Lilly working together on 3D printing for drugs A new research collaboration between Chinese company Triastek, Inc. and Eli Lilly and Company will leverage 3D printing […]

August 19, 2022

News and Trends 27 May 2022

Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites

Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two new U.S. sites. The new facilities are located at Indiana’s LEAP Lebanon Innovation and Research District in Boone County. David A. Ricks, Lilly’s chair and CEO, said: “These new sites will add capacity in support of our growing pipeline of […]

May 27, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Apr 2020

Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M

Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat autoimmune disease in a deal worth €811M if development milestones are met. The UK biotech will receive an upfront payment of €46M from the US big pharma, which will also buy €10M of equity in the company. Sitryx can also […]

April 3, 2020 - 2 minutesmins - By Helen Albert

alzheimers disease phase iii UK 1 e1557338331863

News and Trends 24 Mar 2020

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s disease drug has increased in worth by €38M with a new milestone payment. AC Immune and Eli Lilly modified a deal signed in late 2018 to co-develop a small molecule treatment to slow the progression of Alzheimer’s disease. Specifically, the […]

March 24, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 30 Sep 2019

Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close

Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid €13M to Adocia, after the US Arbitration Association Panel supported Adocia’s claim last year. The payment consists of a milestone payment of €10.1M plus interest. […]

September 30, 2019 - 4 minutesmins - By Editorial Team

More News! 23 Sep 2019

AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I

AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone payment in a deal worth up to €1.6B (CHF 1.7B), which Eli Lilly and AC Immune signed to develop drugs for Alzheimer’s and other neurodegenerative […]

September 23, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Sep 2018

Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics

In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo can outperform Lilly’s fast-acting insulin in keeping sugar levels low after a meal. The trial, which recruited 24 type 1 diabetics, studied the effect of Adocia’s BioChaperone pramlintide insulin on glucose levels right after […]

September 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Feb 2018

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug. After obtaining approval for an injected version, Novo Nordisk is now getting ready […]

February 23, 2018 - 3 minutesmins - By Alexander Burik

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eli Lilly

Lilly to develop Confo pain drug

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Study of injection to treat schizophrenia to begin after $3M payment received

Beyond Biotech podcast 10: Endpoint Health, Nevrargenics, Triastek

Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites

Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close

AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I

Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!